two
new
polyomavirus
pyv
ki
wu
describ
probabl
caus
agent
respiratori
infect
human
current
classifi
polyomavirida
famili
betapolyomaviru
genu
human
polyomaviru
kipyv
human
polyomaviru
wupyv
speci
two
pyv
detect
global
children
immunocompet
adult
detect
rate
rang
wupyv
kipyv
suggest
role
virus
pathogenesi
respiratori
infect
mani
studi
far
demonstr
presenc
wupyv
kipyv
respiratori
tract
symptomat
asymptomat
patient
although
also
found
clinic
sampl
stool
lymphoid
tissu
immunocompromis
immunocompet
individu
coinfect
pathogen
report
patient
kipyv
patient
wupyv
coinfect
kipyv
wupyv
absenc
respiratori
virus
brazil
kipyv
wupyv
found
saliva
immunocompromis
immunocompet
patient
studi
investig
pyv
ki
wu
occur
sever
respiratori
diseas
hospit
patient
acut
respiratori
infect
sari
retrospect
studi
conduct
april
novemb
month
use
sampl
hospit
patient
present
sari
within
day
onset
symptom
includ
fever
dyspnea
cough
children
year
adult
includ
clinic
epidemiolog
inform
obtain
standard
questionnair
inform
consent
previous
obtain
enrol
patient
initi
suspect
influenza
infect
studi
approv
ethic
committe
sao
paulo
feder
univers
cep
nasopharyng
aspir
obtain
children
year
old
patient
naso
oropharyng
swab
collect
accord
brazilian
ministri
health
protocol
manag
influenza
pandem
store
freezer
total
nucleic
acid
extract
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
accord
manufactur
instruct
specimen
test
presenc
respiratori
virus
accord
pcr
protocol
avail
laboratori
influenza
flu
b
flu
b
virus
human
respiratori
syncyti
viru
hrsv
human
rhinoviru
hrv
human
metapneumoviru
hmpv
human
coronaviru
hcov
human
adenoviru
hadv
parainfluenza
viru
piv
wupyv
kipyv
specif
detect
qualit
realtim
pcr
perform
primer
pyvf
pyvr
amplifi
fragment
gene
encod
capsid
protein
common
kipyv
wupyv
two
specif
probe
wupyvp
kipyvp
within
gene
differenti
wupyv
kipyv
virus
concentr
primer
probe
nm
nm
respect
total
reaction
volum
use
onestep
rtpcr
reagent
appli
biosystem
austin
usa
addit
extract
nucleic
acid
parallel
reaction
primer
specif
probe
use
amplifi
fragment
gene
glyceraldehyd
dehydrogenas
gapdh
endogen
control
assess
qualiti
sampl
describ
bergallo
et
al
thermocycl
condit
perform
appli
biosystem
realtim
pcr
system
involv
min
follow
cycl
min
data
collect
reaction
cycl
threshold
valu
ct
adopt
cutoff
chisquar
analysi
fisher
exact
test
use
analyz
occurr
investig
pyv
student
test
independ
sampl
analysi
varianc
anova
use
compar
mean
age
statist
analys
perform
use
openepi
version
http
wwwopenepicom
p
valu
consid
statist
signific
total
patient
present
sari
suspect
due
influenza
treat
sao
paulo
hospit
complex
enrol
patient
sampl
obtain
among
enrol
children
adult
male
mean
age
children
year
median
year
rang
year
mean
age
adult
year
median
rang
year
viral
detect
identifi
patient
detect
rate
wupyv
kipyv
case
wupyv
kipyv
mean
ct
valu
sd
gapdh
endogen
control
sampl
rang
posit
sampl
shown
gapdh
ct
valu
except
one
sampl
posit
wupyv
ct
mean
ct
valu
wupyv
kipyv
rang
shown
bracket
respect
singl
viral
detect
rate
follow
wupyv
kipyv
flu
flu
b
hadv
hcov
hmpv
piv
hrv
hrsv
wupyv
kipyv
coinfect
rate
tabl
compar
viral
detect
pattern
within
patient
includ
studi
among
patient
viral
infect
coinfect
differ
virus
popul
doubl
viral
coinfect
also
infect
wupyv
kipyv
patient
tripl
coinfect
also
posit
wupyv
kipyv
howev
coinfect
wupyv
kipyv
virus
correl
sever
symptom
proport
children
wupyv
kipyv
sampl
multipl
detect
mean
age
children
coinfect
polyomavirus
year
median
year
rang
year
wupyv
infect
kipyv
infect
children
coinfect
respiratori
virus
pyv
younger
coinfect
pyv
rate
among
patient
month
age
respect
p
two
adult
age
year
show
coinfect
wupyv
kipyv
respect
monoinfect
detect
adult
wupyv
infect
median
age
year
rang
year
patient
admit
fever
cough
dyspnea
symptom
prevail
day
radiolog
chest
examin
bacteri
hemocultur
system
antibiot
prophylaxi
conduct
accord
hospit
proceed
clinic
bacteri
pneumonia
investig
current
guidelin
three
patient
report
comorbid
present
differ
state
immunosuppress
length
period
hospit
icu
admiss
shown
tabl
patient
system
lupu
erythematosu
sle
admit
icu
mechan
ventil
due
nosocomi
pneumonia
bacteri
coinfect
patient
without
comorbid
hospit
h
discharg
upon
resolut
dyspnea
role
pyv
pathogenesi
respiratori
infect
well
understood
studi
demonstr
presenc
pyv
wu
ki
asymptomat
popul
howev
rate
polyomaviru
infect
adult
patient
hospit
sari
establish
proport
respiratori
sampl
hospit
patient
sari
posit
wupyv
kipyv
wupyv
kipyv
compar
obtain
author
debat
role
virus
respiratori
infect
ongo
high
rate
coinfect
respiratori
virus
approxim
recent
high
viral
load
kipyv
observ
children
sever
sever
pneumonia
absenc
viral
bacteri
respiratori
infect
suggest
potenti
pathogen
role
kipyv
patient
coinfect
rate
observ
present
studi
mainli
among
children
common
type
wupyvhrv
case
kipyvhrv
kipyvadv
accord
result
alland
et
al
gaynor
et
al
nonetheless
frequent
coinfect
wupyv
kipyv
respiratori
virus
variat
clinic
present
preclud
conclus
associ
infect
diseas
children
interest
find
lower
rate
among
young
children
may
posit
later
acquisit
polyomaviru
infect
older
children
suggest
serolog
molecular
studi
find
monoinfect
polyomavirus
adult
patient
hospit
sari
may
suggest
potenti
pathogen
role
moreov
patient
immunocompromis
one
patient
sle
sever
outcom
requir
icu
admiss
mechan
ventil
perform
retrospect
studi
therefor
possibl
obtain
sampl
lower
respiratori
tract
immunocompromis
patient
immunohistochemistri
situ
hybrid
studi
need
order
understand
possibl
role
viral
latenc
reactiv
dna
virus
adult
patient
especi
among
immunocompromis
regard
prospect
longitudin
studi
larg
sampl
size
includ
immunocompet
immunocompromis
symptomat
asymptomat
patient
could
better
answer
question
